Meeting Banner
Abstract #4370

DCE-MRI Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: Early Prediction of Response and Evaluation of Residual Disease

Alina Tudorica1, Karen Y Oh1, Kathleen A Kemmer1, Megan L Troxell1, Arpana Naik1, Neda Jafarian1, Yiyi Chen1, Stephen YC Chui1, Eric Goranson1, Nicole Roy1, Aneela Afzal1, May Mishal1, Megan L Holtorf1, Charles S Springer1, Xin Li1, and Wei Huang1

1Oregon Health & Science University, Portland, OR, United States

DCE-MRI was performed on 47 breast cancer patients (49 primary tumors) before, during, and after neoadjuvant chemotherapy (NACT). DCE-MRI data were subjected to Tofts model (TM) and Shutter-Speed model (SSM) pharmacokinetic (PK) analysis. Imaging metrics and the corresponding percent changes were correlated with binary pathologic complete response (pCR) and non-pCR endpoints, as well as residual cancer burden (RCB) index values. By NACT midpoint, several DCE-MRI PK parameters and percent changes are good early predictors of pCR vs. non-pCR, while tumor size is a poor predictor. Both PK parameters and tumor size after NACT completion are good markers of RCB. TM and SSM parameters perform equally well for prediction of NACT response and evaluation of RCB.

This abstract and the presentation materials are available to members only; a login is required.

Join Here